[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ajou University School of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":172},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,70,104,125,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644281","navoj-school-based-group-intervention-for-adolescent-mental-health-100644281",false,"NCT07667179","NAVO:J School-Based Group Intervention for Adolescent Mental Health","Effects of a School-Based Group Intervention Using the Digital Mental Health Platform NAVO:J on Adolescent Mental Health","Inclusion Criteria:\n\n* Students who apply for the group intervention program\n* Possession of an internet-enabled smartphone\n* Consent to study participation by both the participant and their legal guardian\n\nExclusion Criteria:\n\n* Inability to install or run \"NAVO:J\" on the participant's smartphone\n* Current participation in another interventional study\n* A medical condition severe enough to preclude the intervention or outcome assessment\n* Judged by the researcher to be unlikely to participate cooperatively through the end of the study",true,"ALL","7 Years","19 Years",{"count":21,"type":22},250,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to determine and verify whether a school-based group intervention using the digital mental health platform NAVO:J can effectively improve the mental health of adolescents-particularly reducing depression, anxiety, and stress while enhancing resilience.",[28,29],"Resilience","Depression","NOT_YET_RECRUITING","2026-06-19",{"date":33,"type":34},"2026-06-24","ACTUAL",{"date":33,"type":22},{"date":37,"type":22},"2027-05-01",{"name":39,"class":40},"Ajou University School of Medicine","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100643552","ai-ecg-algorithm-for-detecting-lv-systolic-dysfunction-100643552","NCT07636759","AI ECG Algorithm for Detecting LV Systolic Dysfunction","Prospective Observational Cohort Study of Deep Learning-based ECG Algorithm for Detecting Left Ventricular Systolic Dysfunction","Inclusion Criteria:\n\n* Adults aged ≥19 years.\n* Patients who underwent both transthoracic echocardiography and 12-lead electrocardiography (ECG) at Ajou University Hospital in the outpatient, inpatient, or emergency department setting.\n* ECG and echocardiography performed within 30 days of each other.\n\nExclusion Criteria:\n\n* Interval between ECG and echocardiography greater than 30 days.\n* Missing or corrupted original ECG waveform data (XML or HL7 format).\n* Presence of an implanted cardiac device, including a permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device.\n* Missing age, sex, or left ventricular ejection fraction (LVEF) data.",{"count":50,"type":22},15000,"1 Month","OBSERVATIONAL","This prospective observational cohort study aims to evaluate the clinical performance of a deep learning-based electrocardiography (ECG) algorithm (DeepECG LVSD) for detecting left ventricular systolic dysfunction (LVSD), defined as left ventricular ejection fraction (LVEF) ≤40%, using transthoracic echocardiography as the reference standard. Approximately 15,000 adult patients undergoing both ECG and echocardiography within 30 days at Ajou University Hospital will be enrolled. Diagnostic performance will be assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. Secondary analyses will evaluate the association between AI-predicted LVSD and 30-day clinical outcomes, including all-cause mortality, emergency department visits, and heart failure rehospitalization.",[55],"HF - Heart Failure",[57,58,59,60],"Heart failure","ECG","Artificial Intelligence","Deep Learning","RECRUITING","2026-06-08",{"date":64,"type":34},"2026-06-10",{"date":66,"type":34},"2026-01-01",{"date":68,"type":22},"2027-12-31",{"name":39,"class":40},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":41},"100623370","youth-suicide-and-self-harm-intervention-clinical-and-biological-outcomes-study-100623370","NCT07395752","Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study","Development and Biological Efficacy Validation of Youth Suicide and Self-Harm Intervention Program","SHIELD","Inclusion Criteria:\n\n1. General Criteria\n\n   * Aged between 15 and 30 years\n   * Obtained informed consent from a parent or legal guardian for participants under 19 years of age\n2. For the Self-Harm Group\n\n   * At least one incident of non-suicidal self-injury (NSSI) within the last 6 months\n   * Self-Harm Screening Inventory (SHSI) score of at least 1 (at least one \"Yes\" response)\n3. For the Suicide Attempt Group\n\n   * Suicide attempt within the last 6 months\n   * Depressive Symptom Inventory-Suicidality Subscale (DSI-SS) score of 3 or higher\n\nExclusion Criteria:\n\n1. Psychiatric and Developmental Conditions\n\n   * History of developmental disorders, including intellectual disability or autism spectrum disorder\n   * Diagnosis of schizophrenia or bipolar disorder\n   * Currently in an acute psychotic state\n2. Medical and Physical Conditions\n\n   * Presence of severe physical illness that interferes with daily life\n   * Presence of metallic substances in the body (e.g., cardiac pacemakers, artificial heart valves) that are incompatible with fMRI\n   * Diagnosis of claustrophobia\n   * Current Treatment and Intervention\n   * Currently receiving regular and active cognitive behavioral therapy (CBT)\n   * Initiation of pharmacological treatment within the last 2 months\n3. Communication and Consent\n\n   * Inability to communicate fluently in Korean\n   * Failure to obtain informed consent from a parent or legal guardian for participants under 19 years of age","15 Years","30 Years",{"count":81,"type":22},100,[25],"The goal of this clinical trial is to develop and evaluate youth-focused intervention programs for suicide and self-harm that are tailored to the psychological, developmental, and cultural characteristics of Korean adolescents and young adults. The study examines whether two structured, mindfulness-based intervention programs-one for middle and high school students and one for young adults-reduce suicidal ideation, self-harm behaviors, depressive symptoms, and emotion-regulation difficulties.\n\nThe study also aims to determine whether these clinical improvements are associated with biological changes, including alterations in resting-state functional brain activity (e.g., ALFF, ReHo, and functional connectivity) and social rhythm patterns.\n\nThe main questions this study seeks to answer are:\n\n* Does the youth suicide and self-harm intervention program reduce suicidal ideation and self-injurious thoughts\u002Fbehaviors?\n* Does the program improve mood, sleep, hopelessness, and emotion regulation?\n* Are improvements in clinical outcomes accompanied by changes in biological markers of suicide risk?\n* Researchers will compare the intervention program to usual care provided in hospitals, schools, and community mental health settings.\n\nParticipants will:\n\n* Participate in the structured suicide\u002Fself-harm intervention program or receive usual care.\n* Complete standardized assessments of mood, sleep, emotion regulation and suicide\u002Fself-harm risk.\n* Undergo biological assessments, including resting-state fMRI and rhythm-related measures, at baseline and follow-up.\n* Be followed for up to 12 weeks.",[85,86,87],"Suicidal Ideation","Self-Injurious Behavior","Suicide, Attempted",[89,90,91,92,93,94,95],"Youth suicide","Suicidal ideation","Suicide attempt","fMRI","Social rhythm","Adolescents","Young adults","2026-05-04",{"date":98,"type":34},"2026-05-08",{"date":100,"type":34},"2025-07-30",{"date":102,"type":22},"2026-12-31",{"name":39,"class":40},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":41},"100517297","the-effect-of-preoperative-maxigesic-on-intraoperative-remifentanil-requirement-100517297","NCT06015711","The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement","The Effect of Preoperative Maxigesic® Administration on Analgesic Nociception Index (ANI) Guided Remifentanil Administration","Inclusion Criteria:\n\n* Adult patients (19-60 years old) with ASA physical status 1, 2, 3\n* Scheduled surgery under general anesthesia\n\nExclusion Criteria:\n\n* The patient does not conset\n* Pregnancy\n* hepatic disorder\n* Renal disorder\n* Asthma\n* Hypersensitivity to the NSAIDs or acetaminophen\n* Patients receiving chronic pain therapy\n* Drug dependence\n* Patients taking psychiatric drugs\n* Alcoholics\n* History of gastrointestinal ulcer or bleeding","60 Years",{"count":113,"type":22},96,[25],"Maxigesic is combined intravenous analgesic of ibuprofen and acetaminphen. The purpose of this study is investigate weather preoperative Maxigesic administration can reduce intraoperative remifentanil requirement.",[117],"Opioid Use","2025-09-30",{"date":120,"type":34},"2025-10-03",{"date":122,"type":34},"2023-08-30",{"date":102,"type":22},{"name":39,"class":40},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100590192","immediate-fracture-risk-after-antihypertensive-drug-initiation-100590192","NCT06964217","Immediate Fracture Risk After Antihypertensive Drug Initiation","Overall Fracture Risk Immediately After Anti-hypertensive Medication Initiation and Temporal Trend in Initial Pharmacotherapy Regimens: An Observational Study","FADI","Inclusion Criteria:\n\n* Individuals with at least 365 days of continuous observation prior to the index date (defined as the date of first antihypertensive medication prescription), with no prior antihypertensive use during that period\n* At least one diagnosis of hypertension (ICD-10 codes I10-I13, I15) recorded within 180 days before the index date\n\nExclusion Criteria (main cohort):\n\n* Any of the following occurring in the 365 days prior to the index date: Hospitalization (inpatient admission, including long-term care facility), transport-related trauma (ICD-10 codes V01-V99), Intentional self-harm (ICD-10 codes X60-X84, Y87), History of pathological fractures (e.g., M84.4, M90.7), Evidence of end-stage renal disease (ESRD), dialysis, kidney transplant, renal osteodystrophy","50 Years","100 Years",{"count":136,"type":22},10000000,"This retrospective observational study aims to evaluate the short-term fracture risk associated with anti-hypertensive medication initiation using a self-controlled case series (SCCS) design and investigate temporal trends of initial anti-hypertensive regimen (monotherapy vs combination therapy) and subsequent fracture incidence. The investigators use the Korean Health Insurance Review and Assessment (HIRA) database to identify adults aged ≥65 with a new prescription for anti-hypertensive therapy and at least one incident non-traumatic fracture.\n\nIn the SCCS analysis, the investigators estimate the within-person incidence rate of overall fractures during the 30-day period following anti-hypertensive initiation compared to control periods. Temporal trends will be recorded through 2013 - 2022.\n\nThe primary outcome is overall non-traumatic fracture occurrence; the secondary outcome is incident proximal hip fracture. These outcomes are defined using diagnostic and procedural codes validated for use in claims data. This study aims to quantify both the immediate temporal association between treatment initiation and fracture risk, and the comparative safety of different initial anti-hypertensive regimens.",[139,140],"Hypertension","Fracture","2025-05-22",{"date":143,"type":34},"2025-05-28",{"date":145,"type":22},"2025-06-01",{"date":147,"type":22},"2025-07-31",{"name":39,"class":40},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":171,"locationsCount":4},"100497004","effectiveness-on-smooth-extubation-according-to-the-administration-time-of-sugammadex-100497004","NCT05751603","Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex","Comparison of Smooth Emergence During Extubation After Anesthesia When Sugammadex is Administered Before and After Extubation","Inclusion Criteria:\n\n* patients undergoing general anesthesia for thyroid surgery.\n* aged between 19 and 64 years\n* American Society of Anesthesiologists physical status I and II\n\nExclusion Criteria:\n\n* patients with malformation or tumor of the upper respiratory tract\n* patients with risk of aspiration\n* obese cases with a BMI \\> 35\n* patients in which tracheal intubation was difficult\n* refusal to participate in research","64 Years",{"count":158,"type":22},66,[25],"After surgery is completed under general anesthesia, extubation is performed after recovery from anesthesia, and during this process, bucking, coughing, and rapid and excessive hemodynamic fluctuations occur very often. These phenomena can lead to high intrathoracic pressure, venous congestion, hematoma formation, or increased bleeding after major neck surgery. (1) They can also increase the risk of aerosol generation, which can transmit infection to health care workers. (2) For this, smooth extubation is required. Methods of administering drugs such as lidocaine, opioids, or dexmedetomidine have been proposed for smooth extubation. (3-5) As a disadvantage, the use of these drugs may be associated with deep sedation and reduced airway reflexes .\n\nRecently, Babu et al. (6) reported that bucking and coughing during extubation could be reduced by changing the timing of administering a muscle relaxant antagonist rather than using these sedative drugs, and thus complications related to extubation could be reduced. In general, in the awakening process, it was common to administer the muscle relaxant at the point of recovery of spontaneous breathing. However, Babu et al. demonstrated the possibility of safe and smooth extubation by changing the timing of administering neostigmine without the use of sedatives or narcotic analgesics, but there are few studies on sugammadex.\n\nTherefore, when recovering from general anesthesia, sugammadex was administered before and immediately after extubation to evaluate and compare smooth extubation (ie, comparison of the frequency of bucking and coughing).",[162,163,164],"Sugammadex","Extubation","Smooth Emergence","2024-07-23",{"date":167,"type":34},"2024-07-25",{"date":169,"type":22},"2024-10-03",{"date":120,"type":22},{"name":39,"class":40},""]